COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study
- Conditions
- COVID-19Liver Cirrhosis
- Registration Number
- NCT04329559
- Lead Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
- Brief Summary
COVID-19 pandemic with SARS-CoV-2 infection has become a global challenge. Though most cases of COVID-19 are mild, the disease can also be fatal. Patients with liver cirrhosis are more susceptible to damage from SARS-CoV-2 infection considering their immunocompromised status. The spectrum of disease and factors that influence the disease course in COVID-19 cases with liver cirrhosis are incompletely defined. This muilticentre observational study (COVID-Cirrhosis-CHESS2002) aims to study the clinical characteristics and risk factors associated with specific outcomes in COVID-19 patients with pre-existing liver cirrhosis.
- Detailed Description
Coronavirus disease 2019 (COVID-19) pandemic with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become a global challenge. Though most cases of COVID-19 are mild, the disease can also be fatal. Patients with liver cirrhosis are more susceptible to damage from SARS-CoV-2 infection considering their immunocompromised status. The spectrum of disease and factors that influence the disease course in COVID-19 cases with liver cirrhosis are incompletely defined. This muilticentre observational study (COVID-Cirrhosis-CHESS2002) aims to study the clinical characteristics and risk factors associated with specific outcomes in COVID-19 patients with pre-existing liver cirrhosis.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 21
-
- Aged 18 or above;
-
- Laboratory-confirmed COVID-19 infection;
-
- Pre-existing liver cirrhosis based on liver biopsy or clinical findings.
-
- Pregnancy or unknown pregnancy status.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method All-cause mortality of COVID-19 patients with liver cirrhosis From illness onset of COVID-19 to death from any cause, up to 365 days 7-day, 28-day, 60-day, 180-day and 365-day all-cause mortality of COVID-19 patients with liver cirrhosis
- Secondary Outcome Measures
Name Time Method Liver-related mortality of COVID-19 patients with liver cirrhosis From illness onset of COVID-19 to death from liver-related cause, up to 365 days 7-day, 28-day, 60-day, 180-day and 365-day liver-related mortality of COVID-19 patients with liver cirrhosis
Baseline characteristics of COVID-19 patients with liver cirrhosis 1 Day Baseline characteristics (laboratory findings, imaging findings, etc.) of COVID-19 patients with liver cirrhosis
Risk factors associated with specific outcomes of COVID-19 patients with liver cirrhosis From hospital admission to death, up to 365 days Risk factors (laboratory findings, imaging findings, etc.) associated with specific outcomes (death, etc.) of COVID-19 patients with liver cirrhosis
Trial Locations
- Locations (15)
The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture
π¨π³Enshi, China
Shenzhen Third People's Hospital
π¨π³Shenzhen, China
The Affiliated Third Hospital of Jiangsu University
π¨π³Zhenjiang, China
Ankang Central Hospital
π¨π³Wuhan, China
Renmin Hospital of Wuhan University
π¨π³Wuhan, China
Dalian Sixth People's Hospital
π¨π³Dalian, China
Guangxi Zhuang Autonomous Region
π¨π³Nanning, China
The Sixth Peoples Hospital of Shenyang
π¨π³Shenyang, China
Suizhou Hospital, Hubei University of Medicine
π¨π³Suizhou, China
Minda Hospital Affiliated to Hubei University for Nationalities
π¨π³Enshi, China
The First Hospital of Lanzhou University
π¨π³Lanzhou, China
The Central Hospital of Lishui City
π¨π³Lishui, China
Tianjin Second People's Hospital
π¨π³Tianjin, China
Wuhan Union Hospital
π¨π³Wuhan, China
Xingtai People's Hospital
π¨π³Xingtai, China